Ocsaar and CYP2C9 Ploymorphism, Is There a Connection Between Pharmacokinetics, Pharmacodynamics and Pharmacogenetics?

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Most Angiotensin receptor blocker's (ARBs) are metabolized by cytochrome P4502C9 (CYP2C9), one of the major isoforms of the cytochrome P450 in human liver microsome. The purpose of this study is to evaluate whether CYP2C9 polymorphism has a significant clinical influence on the blood pressure lowering effect of losartan and valsartan. Weather there is a genetic importance in choosing the right ARB for the right patient.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assaf-Harofeh Medical Center
• Treatments: Losartan; Valsartan

Criteria

Inclusion Criteria:

• The study will include 30 patients with the 3 most prevalent alleles of CYP2C9 *1, *2 and*3, 10 patients of each group.

Exclusion Criteria:

• Patients treated with losartan or valsartan prior to their enrollment to the study,

• Patients with BP below 140 systolic or 90 diastolic in an ambulatory 24 hours BP monitoring, acute coronary syndrome during the 6 months previous to the study,

• Renal failure with creatinin levels above 1.5 mg/dL, hyperkalemia (K > 5 mg/dL),

• Hematologic or solid malignancies or pregnancy.

• Patients will also be excluded from the study if they are known to use one of the drugs inducing or inhibiting the CYP2C9, such as

• rifampicin carbamazepine,

• ethanol,

• phenobarbitone,

• fluconazole,

• amiodarone,

• trimethoprim,

• fluvastatin,

• cimetidine

• chloramphenicol.